4//SEC Filing
McNeill Jonathan 4
Accession 0000950170-24-030484
CIK 0001818794other
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 6:04 AM ET
Size
22.9 KB
Accession
0000950170-24-030484
Insider Transaction Report
Form 4
McNeill Jonathan
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-03-11$5.54/sh+17,825$98,751→ 159,009 total - Sale
Common Stock
2024-03-11$25.48/sh−17,825$454,181→ 141,184 total - Sale
Common Stock
2024-03-11$25.71/sh−1,776$45,661→ 139,408 total - Exercise/Conversion
Stock option (right to buy)
2024-03-08−86,159→ 12,309 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (86,159 underlying) - Exercise/Conversion
Common Stock
2024-03-08$5.54/sh+86,159$477,321→ 227,343 total - Exercise/Conversion
Common Stock
2024-03-08$5.54/sh+3,841$21,279→ 231,184 total - Sale
Common Stock
2024-03-08$26.72/sh−54,648$1,460,195→ 141,873 total - Sale
Common Stock
2024-03-08$25.46/sh−34,663$882,520→ 196,521 total - Sale
Common Stock
2024-03-08$27.31/sh−689$18,817→ 141,184 total - Exercise/Conversion
Stock option (right to buy)
2024-03-08−3,841Exercise: $5.54Exp: 2030-07-30→ Common Stock (3,841 underlying) - Exercise/Conversion
Stock option (right to buy)
2024-03-11−17,825→ 0 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (17,825 underlying)
Footnotes (9)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.25 to $26.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.25 to $27.19, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.39, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.14 to $26.09, inclusive.
- [F5]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.67 to $25.81, inclusive.
- [F7]Includes 132,976 unvested RSUs.
- [F8]The option was granted on July 31, 2020. The shares underlying the option vest over four years in equal quarterly installments beginning on October 31, 2020.
- [F9]The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one ofitsproduct candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined thattheperformance condition had been achieved.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001824673
Filing Metadata
- Form type
- 4
- Filed
- Mar 12, 8:00 PM ET
- Accepted
- Mar 13, 6:04 AM ET
- Size
- 22.9 KB